Gender-related differences in pharmacokinetics and pharmacodynamics;Geschlechtsspezifische Unterschiede in der Pharmakokinetik und -dynamik von Arzneimitteln

Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz

Volumn 48, Issue 5, 2005, Pages 536-540

  Thurmann P A ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

Clinical trials; Drug development; Female gender; Pharmacodynamics; Pharmacokinetics

Indexed keywords

CYTOCHROME P450; GLYCOPROTEIN P; NEW DRUG;

ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; DRUG EFFICACY; DRUG METABOLISM; DRUG RESEARCH; DRUG SAFETY; DRUG SENSITIVITY; DRUG TARGETING; FEMALE; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; INCIDENCE; PHASE 2 CLINICAL TRIAL; POPULATION RESEARCH; SEX DIFFERENCE;

CLINICAL TRIALS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; MALE; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOLOGY; SEX FACTORS;

EID: 19444386101     PISSN: 14369990     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00103-005-1039-0     Document Type: Article

References (53)

1. Schmucker DL, Vesell ES (1993) Underrepresentation of women in clinical drug trials. Clin Pharmacol Ther 54:11-15
2. Fleisch J (2005) Frauen in klinischen Studien. Eine Analyse klinisch-pharmakologischer Fachzeitschriften aus dem Jahre 2001. Inaugural-Dissertation zur Erlangung des Grades eines Doktors der Medizin der Universität Witten/Herdecke
3. Evelyn B, Toigo T, Banks D5 et al. (2001) Women's participation in clinical trials and gender-related labeling. A review of new molecular entities approved 1995-1999. FDA, August 24 www.fda.gov/cder/reports/ womens_health/women_clin_trials.htm
4. Wright DT, Chew NJ (1996) Women as subjects in clinical research. Appl Clin Trials 5:44-54
5. Chen ML, Lee SC, Ng MJ et al. (2000) Pharmacokinetic analysis of bioequivalence trials: Implications for sex-related issues in clinical pharmacology and biopharmaceutics. Clin Pharmacol Ther 68:510-521
6. Cotton DJ, Finkelstein DM, He W et al. (1993) Determinants of accrual of women to a large, multicenter clinical trial program of human immunodeficiency virus infection. J AIDS 6:1322-1328
7. Anastos K, Charney P, Charon RA et al. (1991) Hypertension in women: what is really known? The women's caucus, working group on women's health of the Society of General Internal Medicine. Ann Intern Med 115:287-293
8. Merkatz RB (1993) Women in clinical trials of new drugs. A change in the Food and Drug Administration policy. N Engl J Med 329:292-296
9. Breithaupt-Grögler K, Heger-Mahn D, Klipping C et al. (1997) Klinische Arzneimittelprüfung an Frauen. Überlegungen zum Thema Schwangerschaftsverhütung. Dtsch Ärztebl 94:A-991-993
10. Hutson WR, Roehrkasse RL, Wald A (1989) Influence of gender and menopause on gastric emptying and motility. Gastroenterology 96:11-17
11. 1-acid glycoprotein variants and the effect of glycoforms on their drug-binding capacities. Eur J Clin Pharmacol 58:621-628
12. Wolbold R, Klein K, Burk O et al. (2003) Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38:978-988
13. Krecic-Shepard ME, Barnas CR, Slimko J et al. (2000) Gender-specific effects on verapamil pharmacokinetics and pharmacodynamics in humans. J Clin Pharmacol 40:219-230
14. Krecic-Shepard ME, Park K, Barnas C et al. (2000) Race and sex influence clearance of nifedipine: Results of a population study. Clin Pharm Ther 68:130-142
15. Thürmann PA, Hompesch BC (1998) Influence of gender on the pharmacokinetics and pharmacodynamics of drugs. Int J Clin Pharmacol Ther 36:586-590
16. Luzier AB, Killian A, Wilton JH et al. (1999) Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharm Ther 66:594-601
17. Kendall MJ, Quarterman CP, Jack DB, Beeley L (1982) Metoprolol pharmacokinetics and the oral contraceptive pill. Br J Clin Pharmacol 14:120-122
18. Walle T, Byington RP, Furberg CD et al. (1985) Biologic determinants of propranolol disposition: Results from 1308 patients in the Beta-Blocker Heart Attack Trial. Clin Pharmacol Ther 38:509-518
19. Wuttke H, Rau T, Heide R et al. (2002) Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther 72:429-437
20. Hägg S, Spigset O, Dahlqvist R (2001) Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol 51:169-173
21. Laine K, Tybring G, Bertilsson L (2000) No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects. Clin Pharm Ther 68:151-159
22. Lane HY, Chang YC, Chang WH et al. (1999) Effects of gender and age in plasma levels of clozapine and its metabolites: Analyzed by critical statistics. J Clin Psych 60:36-40
23. Meibohm B, Beierle I, Derendorf H (2002) How important are gender differences in pharmacokinetics? Clin Pharmacokinet 41:329-342
24. Wenk M, Todesco L, Krähenbühl S (2004) Effect of St John's Wort on the activities of CYP 1A2, CYP 3A4, CYP 2D6, N-Acetyltransferase 2, and xanthine oxidase in healthy males and females. Br J Clin Pharmacol 57:495-499
25. Gorski JC, Vannaprasaht S, Hamman MA et al. (2003) The effect of age, sex and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther 74:275-287
26. Menguy R, Desbaillets L, Masters YF, Okabe S (1972) Evidence for a sex-linked difference in aspirin metabolism. Nature 239:102-103
27. Miners JO, Grgurinovich N, Whitehead AG et al. (1986) Influence of gender and oral contraceptive steroids on the metabolism of salicylic acid and acetylsalicylic acid. Br J Clin Pharmacol 22:135-142
28. Miners JO, Attwood J, Birkett DJ (1983) Influence of sex and oral contraceptive steroids on paracetamol metabolism. Br J Clin Pharmacol 16:503-509
29. Mönig H, Baese C, Heidemann HT et al. (1990) Effect of oral contraceptive steroids on the pharmacokinetics of phenprocoumon. Br J Clin Pharmacol 30:115-118
30. Pleym H, Spigset O, Kharasch ED, Dale O (2003) Gender differences in drug effects: Implications for anaesthesiologists. Acta Anaesthesiol Scan 47:241-259
31. Zun LS, Downey LVA, Gossmann W et al. (2002) Gender differences in narcotic-induced emesis in the ED. Am J Emerg Med 20:151-154
32. Giles BE, Walker JS (1999) Gender differences in pain. Curr Opin Anaesthesiol 12:591-595
33. Walker JS, Carmody JJ (1998) Experimental pain in healthy human subjects: Gender differences in nociception and in response to Ibuprofen. Anesth Analg 86:1257-1262
34. Kroboth PD, McAuley JW (1997) Progesterone: Does it affect response to drug? Psychopharmacol Bull 33:297-301
35. Spranger M, Aspey BS, Harrison MJG (1989) Sex difference in antithrombotic effect of aspirin. Stroke 20:34-37
36. Chowienczyk PJ, Watts GF, Cockcroft JR et al. (1994) Sex differences in endothelial function in normal and hypercholesterolaemic subjects. Lancet 344:305-306
37. Dantas AP, Franco MCP, Silva-Antonialli MM et al. (2004) Gender differences in superoxide anion generation in microvessels of hypertensive rats: Role of NAD(P)H-oxidase. Cardiovasc Res 61:22-29
38. Bowles D (2004) A radical idea: Men and women are different. Cardiovasc Res 61:5-6
39. Rathore SS, Wang Y, Krumholz HM (2002) Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med. 347:1403-1411
40. Luchner A, Bröckel U, Muscholl M et al. (2002) Gender-specific differences of cardiac remodellng in subjects with left ventricular dysfunction: A population-based study. Cardiovasc Res 53:720-727
41. Schröder H, Selke W (2000) Arzneimittelverordnungen nach Alter und Geschlecht. In: Schwabe U, Paffrath D (Hrsg) Arzneiverordnungsreport 2000. Springer, Berlin Heidelberg New York Tokyo, S 770-783
42. Martin R, Biswas PN, Freemantle SN et al. (1998) Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: Analysis of 48 cohort studies. Br J Clin Pharmacol 46:505-511
43. Kubota K, Kubota N, Pearce GL, Inman WHW (1996) ACE-inhibitor-induced cough, an adverse drug reaction unrecognised for several years: Studies in Prescription-Event Monitoring. Eur J Clin Pharmacol 49:431-437
44. Makkar RR, Fromm BS, Steinman RT et al. (1993) Female gender as a risk factor for Torsades de Pointes associated with cardiovascular drugs. JAMA 270:2590-2597
45. Ebert SN, Liu XK, Woosley RL (1998) Female gender as a risk factor for drug-induced cardiac arrhythmias: Evaluation of clinical and experimental evidence. J Women's Health 7:547-557
46. Rodriguez I, Kilborn MJ, Liu XK et al. (2001) Drug-induced QT prolongation in women during the menstrual cycle. JAMA 285:1322-1326
47. Schwartz E, Potasman I, Rotenberg M et al. (2001) Serious adverse events of mefloquine in relation to blood level and gender. Am J Trop Med Hyg 65:189-192
48. van Riemsdijk MM, Sturkenboom MCJM, Ditters JM et al. (2004) Low body mass index is associated with an increased risk of neuropsychiatric adverse events and concentration impairment in women on mefloquine. Br J Clin Pharmacol 57:506-512
49. Sloan JA, Goldberg RM, Sargent DJ et al. (2002) Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol 20:1491-1498
50. Gusella M, Toso S, Ferrazzi E et al. (2002) Relationship between body composition parameters and fluorouracil pharmacokientics. Br J Clin Pharmacol 54:131-139
51. http://www.pei.de/gesetze/pdf.htm; 1.10.2004
52. National Institutes of Health (2001) Monitoring adherence to the NIH policy on the inclusion of women and minorities as subjects in clinical research. Comprehensive Report, November
53. Harris DJ, Douglas PS (2000) Enrollment of women in cardiovascular clinical trials funded by the National Heart, Lung, and Blood Institute. N Engl J Med 343:475-480